Regardless of which mechanism(s) turn(s) out to be most significant, our data for the first time raise the possibility that ApoB100 may become a direct molecular target in the therapy of HFD-induced obesity. This evidence concerns the gene APOB and obesity due to melanocortin 4 receptor deficiency.